419 related articles for article (PubMed ID: 27096423)
1. Central nervous system prophylaxis in diffuse large B-cell lymphoma.
Zahid MF; Khan N; Hashmi SK; Kizilbash SH; Barta SK
Eur J Haematol; 2016 Aug; 97(2):108-20. PubMed ID: 27096423
[TBL] [Abstract][Full Text] [Related]
2. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre- and post-rituximab.
Tai WM; Chung J; Tang PL; Koo YX; Hou X; Tay KW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Jul; 90(7):809-18. PubMed ID: 21229246
[TBL] [Abstract][Full Text] [Related]
3. Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.
Guirguis HR; Cheung MC; Mahrous M; Piliotis E; Berinstein N; Imrie KR; Zhang L; Buckstein R
Br J Haematol; 2012 Oct; 159(1):39-49. PubMed ID: 22849793
[TBL] [Abstract][Full Text] [Related]
4. Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity.
Eyre TA; Kirkwood AA; Wolf J; Hildyard C; Mercer C; Plaschkes H; Griffith J; Fields P; Gunawan A; Oliver R; Booth S; Martinez-Calle N; McMillan A; Bishton M; Fox CP; Collins GP; Hatton CSR
Br J Haematol; 2019 Oct; 187(2):185-194. PubMed ID: 31222719
[TBL] [Abstract][Full Text] [Related]
5. [Central nervous system relapse in diffuse large B cell lymphoma: Risk factors].
Sancho JM; Ribera JM;
Med Clin (Barc); 2016 Jan; 146(2):74-80. PubMed ID: 25817451
[TBL] [Abstract][Full Text] [Related]
6. CNS prophylaxis in diffuse large B-cell lymphoma: if, when, how and for whom?
Siegal T; Goldschmidt N
Blood Rev; 2012 May; 26(3):97-106. PubMed ID: 22244544
[TBL] [Abstract][Full Text] [Related]
7. Central Nervous System Prophylaxis Strategies in Diffuse Large B Cell Lymphoma.
Kansara R
Curr Treat Options Oncol; 2018 Sep; 19(11):52. PubMed ID: 30203318
[TBL] [Abstract][Full Text] [Related]
8. Risk-tailored CNS prophylaxis in a mono-institutional series of 200 patients with diffuse large B-cell lymphoma treated in the rituximab era.
Ferreri AJ; Bruno-Ventre M; Donadoni G; Ponzoni M; Citterio G; Foppoli M; Vignati A; Scarfò L; Sassone M; Govi S; Caligaris-Cappio F
Br J Haematol; 2015 Mar; 168(5):654-62. PubMed ID: 25312994
[TBL] [Abstract][Full Text] [Related]
9. Central nervous system involvement in T-cell lymphoma: A single center experience.
Gurion R; Mehta N; Migliacci JC; Zelenetz A; Moskowitz A; Lunning M; Moskowitz C; Hamlin P; Horwitz S
Acta Oncol; 2016 May; 55(5):561-6. PubMed ID: 27046135
[TBL] [Abstract][Full Text] [Related]
10. Influence of Rituximab on Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma and Role of Prophylaxis--A Systematic Review of Prospective Studies.
Ghose A; Elias HK; Guha G; Yellu M; Kundu R; Latif T
Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):451-7. PubMed ID: 25816933
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic CNS directed therapy in systemic diffuse large B cell lymphoma.
Ghose A; Kundu R; Latif T
Crit Rev Oncol Hematol; 2014 Sep; 91(3):292-303. PubMed ID: 24698003
[TBL] [Abstract][Full Text] [Related]
12. The role of central nervous system (CNS) prophylaxis in preventing DLBCL patients from CNS relapse: A network meta-analysis.
Lin Z; Chen X; Liu L; Zeng H; Li Z; Xu B
Crit Rev Oncol Hematol; 2022 Aug; 176():103756. PubMed ID: 35809794
[TBL] [Abstract][Full Text] [Related]
13. How to Decide Which DLBCL Patients Should Receive CNS Prophylaxis.
Hall KH; Panjic EH; Valla K; Flowers CR; Cohen JB
Oncology (Williston Park); 2018 Jun; 32(6):303-9. PubMed ID: 29940062
[TBL] [Abstract][Full Text] [Related]
14. Neuromeningeal prophylaxis for diffuse large B-cell lymphoma.
Kacem K; Zriba S
Tunis Med; 2017 Oct; 95(10):842-846. PubMed ID: 29873053
[TBL] [Abstract][Full Text] [Related]
15. [Isolated central nervous system relapse of diffuse large B-cell lymphoma in the era of immunochemotherapy].
Krmek DZ; Ljubić N; Vrbanić L
Acta Med Croatica; 2012 Dec; 66(5):403-7. PubMed ID: 23814970
[TBL] [Abstract][Full Text] [Related]
16. Central nervous system involvement in diffuse large B-cell lymphoma.
Yamamoto W; Tomita N; Watanabe R; Hattori Y; Nakajima Y; Hyo R; Hashimoto C; Motomura S; Ishigatsubo Y
Eur J Haematol; 2010 Jul; 85(1):6-10. PubMed ID: 20236301
[TBL] [Abstract][Full Text] [Related]
17. Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma.
Abramson JS; Hellmann M; Barnes JA; Hammerman P; Toomey C; Takvorian T; Muzikansky A; Hochberg EP
Cancer; 2010 Sep; 116(18):4283-90. PubMed ID: 20564149
[TBL] [Abstract][Full Text] [Related]
18. Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Ann Hematol; 2016 Oct; 95(10):1661-9. PubMed ID: 27370993
[TBL] [Abstract][Full Text] [Related]
19. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database.
Kumar A; Vanderplas A; LaCasce AS; Rodriguez MA; Crosby AL; Lepisto E; Czuczman MS; Nademanee A; Niland J; Gordon LI; Millenson M; Zelenetz AD; Friedberg JW; Abel GA
Cancer; 2012 Jun; 118(11):2944-51. PubMed ID: 22006274
[TBL] [Abstract][Full Text] [Related]
20. [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].
Shimada K
Brain Nerve; 2011 May; 63(5):467-72. PubMed ID: 21515926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]